Alkermes plc. (ALKS) Borrowing debt
- Total debt · latest quarter (USD): Value (m); Formula and calculation Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted). Period ending 2026-06-30..
- Net cash · latest quarter: Value (m); Formula and calculation Cash and cash equivalents plus current marketable securities less interest-bearing debt; negative net cash is displayed as net debt. Period ending 2026-06-30..
- Debt / assets · latest quarter: Value (m); Formula and calculation Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted) / total assets. Period ending 2026-06-30..
Borrowing debt
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Total debt · latest quarter (USD) | (m) | Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted). Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Net cash · latest quarter | (m) | Cash and cash equivalents plus current marketable securities less interest-bearing debt; negative net cash is displayed as net debt. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Debt / assets · latest quarter | (m) | Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted) / total assets. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Borrowing debt due within one year | 26.50M USD | Long-term Debt, Current Maturities |
| Borrowing debt due after one year | 1.48B USD | Long-term Debt, Excluding Current Maturities |
| Commercial paper | (m) | |
| Cash and current securities | 656.58M USD | Cash and Cash Equivalents, at Carrying Value · Debt Securities, Available-for-sale, Current |
| Borrowing debt | (m) | Long-term Debt, Current Maturities · Long-term Debt, Excluding Current Maturities |
| Total assets | 4.39B USD | Assets |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Total debt | Net cash / debt | Borrowing debt due within one year (USD) | Borrowing debt due after one year (USD) | Commercial paper (USD) | Cash and current securities (USD) | Total assets (USD) | Debt / assets |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | (m) | $26.50M | $1.48B | (m) | $656.58M | $4.39B | (m) |
| 2026-03-31 | (m) | (m) | $26.50M | $1.48B | (m) | $511.86M | $4.26B | (m) |
| 2025-12-31 | (m) | (m) | $0.00 | $0.00 | (m) | $588.22M | $2.49B | (m) |
| 2024-09-30 | (m) | (m) | $3.00M | $285.82M | (m) | $908.86M | $2.16B | (m) |
| 2024-06-30 | (m) | (m) | $3.00M | $286.46M | (m) | $876.12M | $2.21B | (m) |
| 2024-03-31 | (m) | (m) | $3.00M | $287.10M | (m) | $745.05M | $2.12B | (m) |
| 2023-12-31 | (m) | (m) | $3.00M | $287.73M | (m) | $773.49M | $2.14B | (m) |
| 2023-09-30 | (m) | (m) | $3.00M | $288.37M | (m) | $889.15M | $2.28B | (m) |
| 2023-06-30 | (m) | (m) | $3.00M | $289.00M | (m) | $829.05M | $2.19B | (m) |
| 2023-03-31 | (m) | (m) | $3.00M | $289.63M | (m) | $600.46M | $1.92B | (m) |
| 2022-12-31 | (m) | (m) | $3.00M | $290.27M | (m) | $608.47M | $1.96B | (m) |
| 2022-09-30 | (m) | (m) | $3.00M | $290.90M | (m) | $580.18M | $1.94B | (m) |
| 2022-06-30 | (m) | (m) | $3.00M | $291.54M | (m) | $580.97M | $1.96B | (m) |
| 2022-03-31 | (m) | (m) | $3.00M | $292.17M | (m) | $528.87M | $1.98B | (m) |
| 2021-12-31 | (m) | (m) | $3.00M | $292.80M | (m) | $536.31M | $2.02B | (m) |
| 2021-09-30 | (m) | (m) | $3.00M | $293.44M | (m) | $560.30M | $2.00B | (m) |
| 2021-06-30 | (m) | (m) | $3.00M | $294.07M | (m) | $538.35M | $1.94B | (m) |
| 2021-03-31 | (m) | (m) | $3.00M | $294.70M | (m) | $541.00M | $1.88B | (m) |
| 2020-12-31 | (m) | (m) | $2.84M | $272.12M | (m) | $635.03M | $1.95B | (m) |
| 2020-09-30 | (m) | (m) | $2.84M | $272.66M | (m) | $569.38M | $1.88B | (m) |
| 2020-06-30 | (m) | (m) | $2.84M | $273.21M | (m) | $532.56M | $1.80B | (m) |
| 2020-03-31 | (m) | (m) | $2.84M | $273.75M | (m) | $495.99M | $1.83B | (m) |
| 2019-12-31 | (m) | (m) | $2.84M | $274.30M | (m) | $534.98M | $1.81B | (m) |
| 2019-09-30 | (m) | (m) | $2.84M | $274.84M | (m) | $587.18M | $1.76B | (m) |
| 2019-06-30 | (m) | (m) | $2.84M | $275.38M | (m) | $570.29M | $1.75B | (m) |
| 2019-03-31 | (m) | (m) | $2.84M | $275.92M | (m) | $582.13M | $1.76B | (m) |
| 2018-12-31 | (m) | (m) | $2.84M | $276.46M | (m) | $539.29M | $1.83B | (m) |
| 2018-09-30 | (m) | (m) | $2.84M | $277.01M | (m) | $467.09M | $1.76B | (m) |
| 2018-06-30 | (m) | (m) | $2.84M | $277.55M | (m) | $433.51M | $1.75B | (m) |
| 2018-03-31 | (m) | (m) | $2.84M | $278.09M | (m) | $404.56M | $1.74B | (m) |
| 2017-12-31 | (m) | (m) | $3.00M | $278.44M | (m) | $433.50M | $1.80B | (m) |
| 2017-09-30 | (m) | (m) | $3.00M | $278.99M | (m) | $450.10M | $1.75B | (m) |
| 2017-06-30 | (m) | (m) | $3.00M | $279.55M | (m) | $475.11M | $1.73B | (m) |
| 2017-03-31 | (m) | (m) | $3.00M | $280.11M | (m) | $476.42M | $1.73B | (m) |
| 2016-12-31 | (m) | (m) | $3.00M | $280.67M | (m) | $497.23M | $1.73B | (m) |
| 2016-09-30 | (m) | (m) | $3.00M | $282.58M | (m) | $549.46M | $1.71B | (m) |
| 2016-06-30 | (m) | (m) | $63.91M | $283.12M | (m) | $655.98M | $1.79B | (m) |
| 2016-03-31 | (m) | (m) | $64.83M | $283.66M | (m) | $625.39M | $1.79B | (m) |
| 2015-12-31 | (m) | (m) | $65.74M | $284.21M | (m) | $534.78M | $1.86B | (m) |
| 2015-09-30 | (m) | (m) | $66.71M | $286.51M | (m) | $771.76M | $1.88B | (m) |
| 2015-06-30 | (m) | (m) | $6.75M | $348.06M | (m) | $776.77M | $1.91B | (m) |
| 2015-03-31 | (m) | (m) | $6.75M | $349.64M | (m) | $747.46M | $1.92B | (m) |
| 2014-12-31 | (m) | (m) | $6.75M | $351.22M | (m) | $631.17M | $1.92B | (m) |
| 2014-09-30 | (m) | (m) | $6.75M | $352.80M | (m) | $572.57M | $1.84B | (m) |
| 2014-06-30 | (m) | (m) | $6.75M | $354.38M | (m) | $638.49M | $1.86B | (m) |
| 2014-03-31 | (m) | (m) | $6.75M | $355.96M | (m) | $552.27M | $1.84B | (m) |
| 2013-12-31 | (m) | (m) | $6.75M | $357.54M | (m) | $362.23M | $1.58B | (m) |
| 2013-09-30 | (m) | (m) | $6.75M | $359.12M | (m) | $339.43M | $1.51B | (m) |
| 2013-06-30 | (m) | (m) | $6.75M | $360.69M | (m) | $228.54M | $1.48B | (m) |
| 2013-03-31 | (m) | (m) | $6.75M | $362.26M | (m) | $221.35M | $1.47B | (m) |
| 2012-12-31 | (m) | (m) | $6.75M | $362.35M | (m) | $209.30M | $1.41B | (m) |
| 2012-09-30 | (m) | (m) | $6.75M | $363.85M | (m) | $199.45M | $1.37B | (m) |
| 2012-06-30 | (m) | (m) | $3.10M | $441.08M | (m) | $164.37M | $1.45B | (m) |
| 2012-03-31 | (m) | (m) | $3.10M | $441.36M | (m) | $190.45M | $1.44B | (m) |
| 2011-12-31 | (m) | (m) | $3.10M | $441.67M | (m) | $213.43M | $1.51B | (m) |
| 2011-09-30 | (m) | (m) | $2.33M | $441.86M | (m) | $215.56M | $1.50B | (m) |
| 2011-03-31 | (m) | (m) | $0.00 | $0.00 | (m) | $201.32M | $452.45M | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |